Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
About the study
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
Documentation that the patient was exposed to patisiran-LNP at any point starting from 12 weeks before LMP or at any point during pregnancy
EXCLUSION CRITERIA
Exclusion Criteria:
There are no exclusion criteria for participation in this program.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Hereditary Transthyretin-mediated (hATTR) Amyloidosis,Polyneuropathy
Participants needed
10
Est. Completion Date
Oct 12, 2030
Treatment type
Observational
Sponsor
Alnylam Pharmaceuticals
ClinicalTrials.gov identifier
NCT05040373
Study number
ALN-TTR02-010
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?